The prognostic value of CD3+ tumor-infiltrating lymphocytes for stage II colon cancer according to use of adjuvant chemotherapy: A large single-institution cohort study

Translational Oncology

Fang-Shu Ou¹  Edoardo Francini²  Roberto Petrioli³  Stefano Lazzi⁴  Steven R. Alberts⁴  Guido Francini⁴  Harry H. Yoon⁴  Joleen M. Hubbard⁴  Luciana Messuti⁵  Sara Cherri⁵  Virginia Livellara⁵  Salvatora T. Miano⁵  Guido Pesola⁵  Andrea G. Multari⁵  Elena Colombo⁵  Eric G. Wolfe⁵  Serena Bazzurri⁵ 

[1] Corresponding author.;Department of Experimental and Clinical Medicine, University of Florence, Florence 50134, Italy;Department of Human Pathology and Oncology, University of Siena, Siena, Italy;Mayo Clinic, Rochester, MN, USA;Santa Maria Alle Scotte Hospital, Siena, Italy;

关键词: Colorectal cancer;    Post-surgery treatment;    Fluoropyrimidines;    Prognostic marker;    T-cells;   

DOI  :  

来源: DOAJ

【 摘 要 】

Background: High tumor infiltrating lymphocytes (TILs) density was previously shown to be associated with favorable prognosis for patients with colon cancer (CC). However, the impact of TILs on overall survival (OS) of stage II CC patients who received adjuvant chemotherapy (ADJ) or not (no-ADJ) is unknown. We assessed the prognostic value of CD3+ TILs in stage II CC patients according to whether they had ADJ or not. Methods: Patients treated with curative surgery for stage II CC (2002–2013) were selected from the Santa Maria alle Scotte Hospital registry. TILs at the invasive front, center of tumor, and stroma were determined by immunohistochemistry and manually quantified as the rate of TILs/total tissue areas. High TILs (H-TILs) was defined as >20%. Patients were categorized as high or low TILs (L-TILs) and ADJ or no-ADJ. Results: Of the 678 patients included, 137 (20%) received ADJ and 541 (80%) did not. The distribution of the 4 groups were: 16% (L-TIL/ADJ), 64% (L-TIL/no-ADJ), 5% (H-TIL/ADJ), 15% (H-TIL/no-ADJ). Compared to H-TILs/no-ADJ, ADJ patients showed a significantly increased OS (P<.01) regardless of the TILs rate whereas L-TILs/no-ADJ had significantly decreased OS and higher risk of death (HR=1.41; 95% CI, 1.06–1.88; P<.0001). On multivariable analysis, the unfavorable prognostic value of L-TILs (vs. H-TILs) for no-ADJ patients was confirmed (HR=1.36; 95% CI 1.02, 1.82; P=.0373). Conclusion: Low CD3+ TILs rate was associated with shorter OS in those with stage II colon cancer who did not receive adjuvant therapy. Low CD3+ TILs could be considered an additional risk factor for still ADJ-untreated stage II CC patients, which could facilitate clinical decision making.

【 授权许可】

Unknown